Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 21;12(1):74–89. doi: 10.1158/2159-8290.CD-21-0715

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Pretreatment HER3 membrane expression and association with BOR. BOR was assessed by BICR in patients treated with HER3-DXd at 5.6 mg/kg (43 of 57 patients evaluable for HER3 membrane expression). A, Distribution of pretreatment HER3 membrane H-score (0–300). B, Pretreatment HER3 membrane H-score and association with time since last treatment with EGFR TKI. C and D, Pretreatment HER3 membrane H-score and confirmed BOR (cBOR). — Pretreatment HER3 membrane expression and association with BOR. BOR was assessed by BICR in patients treated with HER3-DXd at 5.6 mg/kg (43 of 57 patients evaluable for HER3 membrane expression). A, Distribution of pretreatment HER3 membrane H-score (0–300). B, Pretreatment HER3 membrane H-score and association with time since last treatment with EGFR TKI. C and D, Pretreatment HER3 membrane H-score and confirmed BOR (cBOR).